Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development

PR Newswire May 11, 2016

Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs

PR Newswire May 9, 2016

Synthetic Biologics Reports First Quarter 2016 Operational Highlights and Financial Results

PR Newswire May 5, 2016

Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results

PR Newswire March 10, 2016

Synthetic Biologics to Present at the 28th Annual ROTH Conference

PR Newswire March 9, 2016

Synthetic Biologics to Report 2015 Year End Results on March 10, 2016

PR Newswire March 3, 2016

Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea

PR Newswire March 1, 2016

Synthetic Biologics Reports Allowance Of Key U.S. Patent Covering SYN-010 For Novel Treatment Of IBS-C

Press Releases February 17, 2016

Astronics Sees FY Revenue $665M to $725M vs $726M est

Press Releases February 17, 2016

Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

Press Releases February 17, 2016

Synthetic Biologics to Participate in Fireside Chat at RBC Capital Markets' Global Healthcare Conference

Press Releases February 16, 2016

Synthetic Biologics to Present at the 2016 BIO CEO & Investor Conference

PR Newswire February 3, 2016

Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta(TM) Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis

PR Newswire February 2, 2016

Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire January 19, 2016

Synthetic Biologics to Present at the Biotech Showcase(TM) 2016 Conference

PR Newswire January 6, 2016

Timing is Crucial, Upside Analysis - Analyst Notes on Mercury Systems, Synthetic Biologics, CRA International and Altisource Asset Management

Accesswire December 15, 2015

Promising Clinical Trials Coming in 2016 for IBD, Prostate Cancer and Spinal Cord Injuries

Accesswire December 15, 2015

Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire December 8, 2015

Synthetic Biologics to Webcast Microbiome Clinical Program Seminar

PR Newswire December 7, 2015

Synthetic Biologics Announces Positive Topline Results from First Phase 2a Clinical Trial of SYN-004, the Company's Candidate for the Prevention of C. difficile Infection

PR Newswire December 1, 2015